Photodynamic Therapy for Prostatic Carcinoma in a Dog

Lucroy, Michael D.; Bowles, Mary; Higbee, Russell G.; Blaik, Margaret A.; Ritchey, Jerry W.; Ridgway, Tisha D.

doi:10.1111/j.1939-1676.2003.tb02440.x

Cited by 29 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first case of treating spontaneous canine prostate cancer with ALA-PDT has been reported (without postmortem examination) [29]. Here, the effectiveness of Tookad-PDT on prostate cancer was evaluated in one dog with spontaneous occurring prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Treatment options for prostatic neoplasia include nonsteroidal anti‐inflammatory drugs (NSAIDs), chemotherapy (maximum tolerated dose [MTD], metronomic, and intra‐arterial), radiation therapy, photodynamic therapy, and surgery. Surgical options include curative‐intent total prostatectomy and palliative‐intent procedures, such as partial prostatectomy, transurethral resection, urethral stenting, and urinary diversion procedures …”

Section: Introductionmentioning

confidence: 99%

“…Survival of dogs with urogenital carcinoma has been improved by NSAIDs alone and combined with chemotherapeutic agents such as mitoxantrone and carboplatin . Survival times in dogs with prostatic malignancies vary widely, from 17 to 654 days, depending on the stage at diagnosis and treatment pursued . Furthermore, current therapeutic strategies have been associated with poor response and high complication rates.…”

Section: Introductionmentioning

confidence: 99%

Total prostatectomy as a treatment for prostatic carcinoma in 25 dogs

Bennett¹,

Matz

Henderson

et al. 2018

Veterinary Surgery

View full text Add to dashboard Cite

show abstract

“…After each PDT session, the dog had an improvement in clinical signs, with a combined PFI of 48 weeks. Long‐term results from one male dog have been previously reported (Lucroy et al ., in press).…”

Section: Resultsmentioning

confidence: 79%

Preclinical evaluation of 5‐aminolevulinic acid‐based photodynamic therapy for canine transitional cell carcinoma

Lucroy

Ridgway

Peavy

et al. 2003

Vet Comparative Oncology

View full text Add to dashboard Cite

As a prelude to photodynamic therapy, 5-aminolevulinic acid (ALA) was given orally to healthy dogs. ALA-induced protoporphyrin IX (PpIX) fluorescence significantly increased in the mucosa of the urinary bladder in an ALA dose-dependent fashion. Vomiting occurred after ALA administration in 70% of the dogs but did not affect PpIX fluorescence. ALA-based photodynamic therapy (PDT) of the urinary bladder in healthy dogs caused only submucosal oedema within the bladder wall. No haematologic or serum biochemistry abnormalities were observed after ALA administration. Microscopic haematuria was observed in all the dogs after PDT but was mild and self limiting. ALA-based PDT was administered to six dogs with transitional cell carcinoma (TCC) of the lower urinary tract. ALA-based PDT resulted in tumour progression-free intervals from 4 to 34 weeks in five dogs; one dog with pre-existing hydronephrosis died shortly after PDT. Dogs with TCC represent an outbred, spontaneous, tumour model for developing PDT protocols for humans with bladder cancer.

show abstract

Photodynamic Therapy for Prostatic Carcinoma in a Dog

Cited by 29 publications

References 9 publications

Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer

Studies of a vascular‐acting photosensitizer, Pd‐bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer

Total prostatectomy as a treatment for prostatic carcinoma in 25 dogs

Preclinical evaluation of 5‐aminolevulinic acid‐based photodynamic therapy for canine transitional cell carcinoma

Contact Info

Product

Resources

About